NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

NCT07146113

SuspendedN/A

Sponsor: AstraZeneca

Conditions: Prostate Cancer

Countries: Russia

A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation

Eligibility overview

Sex: MALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Male patients aged ≥ 18 years old;
2. Signed ICF, including consent for FFPE tumor tissue sample testing;
3. De novo histologically confirmed high-aggressive (Gleason 8-10) mPC;
4. Diagnosis of mPC (metastatic prostate cancer) within 2 years prior to inclusion;
5. Availability of source medical documentation;
6. Presence of biopsy FFPE tumor tissue sample, obtained as part of standard clinical practice, which will be used for biomarker testing;
7. Unknown HRRm status.

Exclusion Criteria:

1\. Participation in any interventional trial since the mPC diagnosis.

Locations (16)

Arkhangelsk, Russia
Barnaul, Russia
Chelyabinsk, Russia
Irkutsk, Russia
Krasnodar, Russia
Krasnoyarsk, Russia
Moscow, Russia
Nizhny Novgorod, Russia
Obninsk, Russia
Omsk, Russia
Saint Petersburg, Russia
Saransk, Russia
Tomsk, Russia
Tyumen, Russia
Ufa, Russia
Yekaterinburg, Russia